MX354256B - Derivados de fluoreno, antraceno, xanteno, dibenzosuberona y acridina y usos de ellos. - Google Patents
Derivados de fluoreno, antraceno, xanteno, dibenzosuberona y acridina y usos de ellos.Info
- Publication number
- MX354256B MX354256B MX2012009228A MX2012009228A MX354256B MX 354256 B MX354256 B MX 354256B MX 2012009228 A MX2012009228 A MX 2012009228A MX 2012009228 A MX2012009228 A MX 2012009228A MX 354256 B MX354256 B MX 354256B
- Authority
- MX
- Mexico
- Prior art keywords
- agents
- dibenzosuberone
- xanthene
- acridine
- fluorene
- Prior art date
Links
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 title abstract 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 title abstract 4
- BMVWCPGVLSILMU-UHFFFAOYSA-N 5,6-dihydrodibenzo[2,1-b:2',1'-f][7]annulen-11-one Chemical compound C1CC2=CC=CC=C2C(=O)C2=CC=CC=C21 BMVWCPGVLSILMU-UHFFFAOYSA-N 0.000 title abstract 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 title abstract 2
- 125000003983 fluorenyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 title abstract 2
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 239000013043 chemical agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Se presentan agentes químicos, como por ejemplo derivados de disulfonamida de fluoreno, antraceno, xanteno, dibenzosuberona, y acridina, y estructuras de anillos heterocíclicos similares, incluyendo sus sales, que actúan como agentes anticáncer y antitumor, especialmente cuando tales agentes modulan la actividad de la vía de señalización Wnt/ß-catenina, y sirven para reducir los niveles de ß-catenina presentes en células, como por ejemplo células cancerosas, o en donde los agentes modulan los niveles de expresión génica en sistemas celulares, incluyendo células cancerosas, junto con métodos para la preparación de tales agentes, así como composiciones farmacéuticas que contienen tales agentes como ingredientes activos y métodos para su utilización como agentes terapéuticos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92859207P | 2007-05-10 | 2007-05-10 | |
US99915307P | 2007-10-15 | 2007-10-15 | |
PCT/US2008/006015 WO2008140792A1 (en) | 2007-05-10 | 2008-05-09 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX354256B true MX354256B (es) | 2018-02-20 |
Family
ID=40002552
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009011970A MX2009011970A (es) | 2007-05-10 | 2008-05-09 | Derivados de fluoreno, antraceno, xanteno, dibenzosuberona y acridina y usos de ellos. |
MX2012009228A MX354256B (es) | 2007-05-10 | 2008-05-09 | Derivados de fluoreno, antraceno, xanteno, dibenzosuberona y acridina y usos de ellos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009011970A MX2009011970A (es) | 2007-05-10 | 2008-05-09 | Derivados de fluoreno, antraceno, xanteno, dibenzosuberona y acridina y usos de ellos. |
Country Status (17)
Country | Link |
---|---|
US (3) | US8129519B2 (es) |
EP (1) | EP2152258B1 (es) |
JP (2) | JP5782586B2 (es) |
KR (1) | KR101486026B1 (es) |
CN (2) | CN101730531A (es) |
AU (1) | AU2008251800B2 (es) |
CA (2) | CA2871493C (es) |
DK (1) | DK2152258T3 (es) |
ES (1) | ES2584188T3 (es) |
HU (1) | HUE029155T2 (es) |
IL (2) | IL202039A (es) |
MX (2) | MX2009011970A (es) |
NZ (2) | NZ597731A (es) |
PL (1) | PL2152258T3 (es) |
PT (1) | PT2152258T (es) |
WO (1) | WO2008140792A1 (es) |
ZA (1) | ZA200907859B (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101730531A (zh) * | 2007-05-10 | 2010-06-09 | 阿瓦隆药品公司 | 芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途 |
EP2188293B1 (en) * | 2007-08-15 | 2019-05-01 | Merck Sharp & Dohme Corp. | 6-substituted sulfonyl azabicycloý3.2.1¨octanes useful to inhibit 11 -hydroxysteroid dehydrogenase type-1 |
CA2770116C (en) | 2009-08-10 | 2018-03-13 | Epitherix, Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
KR101161290B1 (ko) | 2009-10-16 | 2012-07-02 | 에스에프씨 주식회사 | 축합방향족화합물 및 이를 이용한 유기전계발광소자 |
PT3001903T (pt) | 2009-12-21 | 2017-12-18 | Samumed Llc | 1h-pirazolo[3,4-b]piridinas e usos terapêuticos destas |
IN2014CN02646A (es) | 2011-09-14 | 2015-08-07 | Samumed Llc | |
BR112014010584A2 (pt) * | 2011-11-06 | 2017-05-02 | Beta Cat Pharmaceuticals Llc | métodos de tratamento de doenças e distúrbios relacionados à atividade da proteína 1 (tbl1) beta-similar a transducina, incluindo neoplasia mieloproliferativa e leucemia mieloide crônica |
US20130123281A1 (en) * | 2011-11-11 | 2013-05-16 | Beta Cat Pharmaceuticals, Llc | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
PT2770994T (pt) | 2012-05-04 | 2019-11-04 | Samumed Llc | 1h-pirazolo[3,4-b]piridinas e utilizações terapêuticas destas |
EP2943198B1 (en) | 2013-01-08 | 2019-07-17 | Samumed, LLC | 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof |
WO2016040188A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
ES2838923T3 (es) * | 2014-10-24 | 2021-07-02 | Koninklijke Philips Nv | Pronóstico médico y predicción de la respuesta a tratamiento usando múltiples actividades de la ruta de señalización celular |
JP2018523705A (ja) * | 2015-07-28 | 2018-08-23 | ベータ・キャット・ファーマシューティカルズ・インコーポレイテッド | アントラセン−9,10−ジオンジオキシム化合物プロドラッグ及びその使用 |
US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
WO2017024010A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
WO2017023972A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10519169B2 (en) | 2015-08-03 | 2019-12-31 | Samumed, Llc | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017024021A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
US10285982B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10231956B2 (en) | 2015-08-03 | 2019-03-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017023993A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10329309B2 (en) | 2015-08-03 | 2019-06-25 | Samumed, Llc | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017023984A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
WO2017023989A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10166218B2 (en) | 2015-08-03 | 2019-01-01 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10226448B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
WO2017023988A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10206909B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017023986A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof |
WO2017058716A1 (en) * | 2015-09-28 | 2017-04-06 | Vivace Therapeutics, Inc. | Tricyclic compounds |
EP3370721A4 (en) | 2015-11-06 | 2019-05-22 | Samumed, LLC | TREATMENT OF OSTEOARTHRITIS |
JP7010851B2 (ja) | 2016-06-01 | 2022-02-10 | バイオスプライス セラピューティクス インコーポレイテッド | N-(5-(3-(7-(3-フルオロフェニル)-3H-イミダゾ[4,5-c]ピリジン-2-イル)-1H-インダゾール-5-イル)ピリジン-3-イル)-3-メチルブタンアミドを調製するための方法 |
CN106106481B (zh) * | 2016-06-16 | 2019-06-28 | 湖北工业大学 | 一种棉铃虫甾醇载体蛋白2抑制剂及其虚拟筛选方法 |
BR112019008061A2 (pt) | 2016-10-21 | 2019-09-17 | Samumed Llc | métodos de uso de indazol-3-carboxamidas e seu uso como inibidores da via de sinalização de wnt/b-catenina |
US10758523B2 (en) | 2016-11-07 | 2020-09-01 | Samumed, Llc | Single-dose, ready-to-use injectable formulations |
WO2018118711A1 (en) * | 2016-12-19 | 2018-06-28 | The Trustees Of Columbia University In The City Of New York | Small molecule ferroptosis inducers |
JP7159302B2 (ja) * | 2017-06-02 | 2022-10-24 | イテリオン・セラピューティクス・インコーポレイテッド | 線維性疾患の治療のための方法 |
CA3103629A1 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
US11136307B1 (en) * | 2020-09-29 | 2021-10-05 | Iterion Therapeutics, Inc. | Crystalline form of tegavivint, method of preparation, and use thereof |
CN117567385B (zh) * | 2023-11-23 | 2024-04-30 | 中国人民解放军军事科学院军事医学研究院 | 一种靶向clec5a的小分子抑制剂及其应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3627791A (en) * | 1968-11-21 | 1971-12-14 | Richardson Merrell Inc | Bis(aminoalkylsulfamoyl) anthraquinones |
US3983248A (en) | 1968-11-21 | 1976-09-28 | Richardson-Merrell Inc. | Bis(aminoalkylsulfamoyl)anthraquinone antiviral agents |
US3829578A (en) * | 1970-12-10 | 1974-08-13 | Richardson Merrell Inc | Antiviral compositions containing bis-basic ethers and thioethers of xanthene and xanthen-9-ones and methods of treating viruses therewith |
US3714194A (en) * | 1971-06-09 | 1973-01-30 | Upjohn Co | Di(azidosulfonyl)xanthones |
US3919211A (en) * | 1973-02-12 | 1975-11-11 | American Home Prod | 9-Oxoxanthene-N,N{40 -bis(substituted)-2,7-disulfonamides |
US3981248A (en) * | 1975-02-28 | 1976-09-21 | Hall Ski-Lift Company, Inc. | Timing gate for ski-lifts |
US4250097A (en) * | 1978-03-08 | 1981-02-10 | Syntex (U.S.A.) Inc. | Compositions for and a method of preventing diabetic complications |
US4276224A (en) * | 1978-06-07 | 1981-06-30 | Ciba-Geigy Corporation | Anthraquinone sulphonamide compounds and preparation |
DE3044072A1 (de) * | 1980-11-24 | 1982-07-15 | Hoechst Ag, 6000 Frankfurt | Bis-aminomehtyl-anthrachinon-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung |
IT1223302B (it) | 1987-09-16 | 1990-09-19 | Baldacci Lab Spa | Composti solfonamido derivati inibitori del sistema enzimatico aldoso-reduttasi e composizioni farmaceutiche che li contengono |
HUT67314A (en) * | 1993-04-09 | 1995-03-28 | Egyt Gyogyszervegyeszeti Gyar | Process for prepg. new trisubstituted cykloalkane deriv.s and pharmaceutical compn.s contg. them |
US7160896B2 (en) * | 2000-07-07 | 2007-01-09 | Cancer Research Technology Limited | Therapeutic acridone and acridine compounds |
EP1307117A1 (en) * | 2000-08-10 | 2003-05-07 | BENETTON GROUP S.p.A. | Sports shoe |
KR20040075934A (ko) * | 2002-01-15 | 2004-08-30 | 캔써 리서치 테크놀로지 리미티드 | 치료용 아크리돈 및 아크리딘 화합물 |
US6693136B1 (en) * | 2002-07-26 | 2004-02-17 | Abbott Laboratories | Fluorenes and anthracenes that inhibit P2X3 and P2X2/3 containing receptors |
EP1871420A4 (en) * | 2005-04-15 | 2010-09-22 | Univ North Carolina | PROCESS FOR ENABLING CELL SURVIVAL VIA NEUROTROPHINE MIMETICS |
CN101730531A (zh) * | 2007-05-10 | 2010-06-09 | 阿瓦隆药品公司 | 芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途 |
-
2008
- 2008-05-09 CN CN200880023589A patent/CN101730531A/zh active Pending
- 2008-05-09 EP EP08754344.3A patent/EP2152258B1/en active Active
- 2008-05-09 HU HUE08754344A patent/HUE029155T2/hu unknown
- 2008-05-09 US US12/451,313 patent/US8129519B2/en active Active
- 2008-05-09 DK DK08754344.3T patent/DK2152258T3/en active
- 2008-05-09 NZ NZ597731A patent/NZ597731A/xx unknown
- 2008-05-09 ES ES08754344.3T patent/ES2584188T3/es active Active
- 2008-05-09 PL PL08754344T patent/PL2152258T3/pl unknown
- 2008-05-09 MX MX2009011970A patent/MX2009011970A/es active IP Right Grant
- 2008-05-09 KR KR1020097025845A patent/KR101486026B1/ko active IP Right Grant
- 2008-05-09 AU AU2008251800A patent/AU2008251800B2/en active Active
- 2008-05-09 MX MX2012009228A patent/MX354256B/es unknown
- 2008-05-09 JP JP2010507482A patent/JP5782586B2/ja active Active
- 2008-05-09 NZ NZ581647A patent/NZ581647A/en unknown
- 2008-05-09 PT PT87543443T patent/PT2152258T/pt unknown
- 2008-05-09 CA CA2871493A patent/CA2871493C/en active Active
- 2008-05-09 CA CA2686402A patent/CA2686402C/en active Active
- 2008-05-09 WO PCT/US2008/006015 patent/WO2008140792A1/en active Application Filing
- 2008-05-09 CN CN201810249295.4A patent/CN108314663B/zh active Active
-
2009
- 2009-11-09 ZA ZA2009/07859A patent/ZA200907859B/en unknown
- 2009-11-10 IL IL202039A patent/IL202039A/en active IP Right Grant
-
2012
- 2012-01-30 US US13/361,761 patent/US9120754B2/en active Active
-
2014
- 2014-03-27 JP JP2014066444A patent/JP6352017B2/ja active Active
-
2015
- 2015-01-21 IL IL236827A patent/IL236827A/en active IP Right Grant
- 2015-07-09 US US14/795,709 patent/US9446021B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX354256B (es) | Derivados de fluoreno, antraceno, xanteno, dibenzosuberona y acridina y usos de ellos. | |
ECSP10010197A (es) | Derivados de piridina y pirazina útiles en el tratamiento de trastornos de proliferación celular | |
GEP20104994B (en) | Tetrahydroindolone and tetrahydroindazolone derivatives | |
ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
UY30183A1 (es) | Derivados de quinolina | |
NZ595372A (en) | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | |
EA201200618A1 (ru) | Производные хроменона с антиопухолевой активностью | |
UY33752A (es) | DERIVADOS DE IMIDAZO[1,2-b]PIRIDAZINA E IMIDAZO[4,5-B]PIRIDINA COMO INHIBIDORES DE JAK | |
MX2010001535A (es) | Derivados de acido azabifenilaminobenzoico como inhibidores de la dihidroorotato deshidrogenasa. | |
CO6541643A2 (es) | Derivados de imidazopirina como inhibidores de jak | |
NI201000003A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
CO6390107A2 (es) | Derivados de pirimidin indol para el tratamiento de cáncer. | |
UY29092A1 (es) | Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
MX2012014017A (es) | Derivados de heteroaril imidazolona como inhibidores de jak. | |
WO2007098086A3 (en) | Hydroxypiperidine derivatives and uses thereof | |
CL2007001710A1 (es) | Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras. | |
NO20090251L (no) | Camptotecinderivater med antitumoraktivitet | |
UY28271A1 (es) | Compuestos químicos | |
MX2009013501A (es) | Compuestos piperidinicos y sus usos. | |
IL174787A0 (en) | Use of cell lines to produce active therapeutic proteins | |
WO2005016264A3 (en) | Diamine derivatives of quinone and uses thereof | |
UY28366A1 (es) | Compuestos químicos | |
IL209270A (en) | Compounds containing tricyclic nitrogen and their use as antibacterial | |
ZA202308118B (en) | Cdk inhibitor |